Skip to content

Study · Animal study (in vivo) · cat · 2011

9 results

The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats.

Gilor C, Graves TK, Gilor S, Ridge TK, Rick M

Domestic animal endocrinology6 Apr 2011Cited by 32 (Europe PMC)

PMID21645806 (opens in a new tab)DOI10.1016/j.domaniend.2011.03.001 (opens in a new tab)PepBankPUB-21645806
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In healthy cats, exenatide increased serum insulin within 15 minutes.

    In plain wordsIn cats, exenatide increased blood insulin within 15 minutes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseEarly insulin concentration
    Study

    catn = 9

    healthy neutered cats
    Comparator
    before injection
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 μg/kg · subcutaneousAs given in this study (cat).

    Measurements

    Insulin fold increase
    2.4 fold
    within 15 min

    Source sentences

    Summary
    After exenatide injection, insulin serum concentrations increased significantly (2.4-fold; range 1.0- to 9.2-fold; P = 0.004) within 15 min.
    2 context sentences
    Summary · context
    Nine young, healthy, neutered, purpose-bred cats were used in a randomized, cross-over design.
    Summary · context
    Two isoglycemic glucose clamps (mimicking the BG concentration during the oral glucose tolerance test) were performed in each cat on separate days, one without prior treatment (IGC) and the second with exenatide (1 μg/kg) injected subcutaneously 2 h before (ExIGC).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In healthy cats, an initial insulin rise after exenatide was followed by a mild decrease in blood glucose.

    In plain wordsIn cats, blood glucose decreased mildly after the initial insulin rise with exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBlood glucose after injection
    Study

    catn = 9

    healthy neutered cats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 μg/kg · subcutaneousAs given in this study (cat).

    Source sentences

    Summary
    This was followed by a mild decrease in BG concentration and a return of insulin concentration to baseline despite a continuous increase in serum exenatide concentrations.
    2 context sentences
    Summary · context
    Nine young, healthy, neutered, purpose-bred cats were used in a randomized, cross-over design.
    Summary · context
    Two isoglycemic glucose clamps (mimicking the BG concentration during the oral glucose tolerance test) were performed in each cat on separate days, one without prior treatment (IGC) and the second with exenatide (1 μg/kg) injected subcutaneously 2 h before (ExIGC).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In healthy cats, insulin returned to baseline despite continuously increasing serum exenatide.

    In plain wordsIn cats, insulin returned to baseline while blood exenatide continued to increase.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeInsulin return to baseline
    Study

    catn = 9

    healthy neutered cats
    Comparator
    baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 μg/kg · subcutaneousAs given in this study (cat).

    Source sentences

    Summary
    This was followed by a mild decrease in BG concentration and a return of insulin concentration to baseline despite a continuous increase in serum exenatide concentrations.
    2 context sentences
    Summary · context
    Nine young, healthy, neutered, purpose-bred cats were used in a randomized, cross-over design.
    Summary · context
    Two isoglycemic glucose clamps (mimicking the BG concentration during the oral glucose tolerance test) were performed in each cat on separate days, one without prior treatment (IGC) and the second with exenatide (1 μg/kg) injected subcutaneously 2 h before (ExIGC).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In healthy cats, insulin AUC was higher during the glucose clamp with exenatide than without it.

    In plain wordsIn cats, total insulin exposure during a glucose clamp was higher with exenatide than without it.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulin AUC
    Study

    catn = 9

    healthy neutered cats
    Comparator
    isoglycemic clamp without exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 μg/kg · subcutaneousAs given in this study (cat).

    Measurements

    Insulin AUC ratio
    2 ratio
    ExIGC versus IGC

    Source sentences

    Summary
    Insulin area under the curve (AUC) during ExIGC was significantly higher than insulin AUC during IGC (AUC ratio, 2.0 ± 0.4; P = 0.03).
    2 context sentences
    Summary · context
    Nine young, healthy, neutered, purpose-bred cats were used in a randomized, cross-over design.
    Summary · context
    Two isoglycemic glucose clamps (mimicking the BG concentration during the oral glucose tolerance test) were performed in each cat on separate days, one without prior treatment (IGC) and the second with exenatide (1 μg/kg) injected subcutaneously 2 h before (ExIGC).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In healthy cats, total infused glucose did not differ significantly between clamps with and without exenatide.

    In plain wordsIn cats, total infused glucose did not differ significantly between clamps with and without exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeTotal infused glucose
    Study

    catn = 9

    healthy neutered cats
    Comparator
    isoglycemic clamp without exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 μg/kg · subcutaneousAs given in this study (cat).

    Source sentences

    Summary
    Total glucose infused was not significantly different between IGC and ExIGC.
    2 context sentences
    Summary · context
    Nine young, healthy, neutered, purpose-bred cats were used in a randomized, cross-over design.
    Summary · context
    Two isoglycemic glucose clamps (mimicking the BG concentration during the oral glucose tolerance test) were performed in each cat on separate days, one without prior treatment (IGC) and the second with exenatide (1 μg/kg) injected subcutaneously 2 h before (ExIGC).
  6. 06AnimalAnimal study (in vivo)Pharmacokinetics

    In healthy cats, exenatide was detectable in plasma 15 minutes after injection.

    In plain wordsIn cats, exenatide was detectable in blood 15 minutes after injection.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableEarly plasma detection
    Study

    catn = 9

    healthy neutered cats
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1 μg/kg · subcutaneousAs given in this study (cat).

    Measurements

    Detection time
    15 min
    after injection

    Source sentences

    Summary
    Exenatide was detectable in plasma at 15 min after injection.
    2 context sentences
    Summary · context
    Nine young, healthy, neutered, purpose-bred cats were used in a randomized, cross-over design.
    Summary · context
    Two isoglycemic glucose clamps (mimicking the BG concentration during the oral glucose tolerance test) were performed in each cat on separate days, one without prior treatment (IGC) and the second with exenatide (1 μg/kg) injected subcutaneously 2 h before (ExIGC).
  7. 07AnimalAnimal study (in vivo)Pharmacokinetics

    In healthy cats, mean exenatide concentration peaked at 45 minutes and returned to baseline by 75 minutes.

    In plain wordsIn cats, blood exenatide peaked at 45 minutes and returned to baseline by 75 minutes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicablePeak and baseline concentration timing
    Study

    catn = 9

    healthy neutered cats
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1 μg/kg · subcutaneousAs given in this study (cat).

    Measurements

    Peak time
    45 min
    after injection
    Return to baseline
    75 min
    after injection

    Source sentences

    Summary
    The mean exenatide concentration peaked at 45 min and then returned to baseline by 75 min.
    2 context sentences
    Summary · context
    Nine young, healthy, neutered, purpose-bred cats were used in a randomized, cross-over design.
    Summary · context
    Two isoglycemic glucose clamps (mimicking the BG concentration during the oral glucose tolerance test) were performed in each cat on separate days, one without prior treatment (IGC) and the second with exenatide (1 μg/kg) injected subcutaneously 2 h before (ExIGC).
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In healthy cats, no adverse reactions to exenatide were observed.

    In plain wordsIn cats, no adverse reactions to exenatide were observed.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableAdverse reactions
    Study

    catn = 9

    healthy neutered cats
    Outcome group
    Adverse events · Whole body
    Studied dose
    1 μg/kg · subcutaneousAs given in this study (cat).

    Source sentences

    Summary
    No adverse reactions to exenatide were observed.
    2 context sentences
    Summary · context
    Nine young, healthy, neutered, purpose-bred cats were used in a randomized, cross-over design.
    Summary · context
    Two isoglycemic glucose clamps (mimicking the BG concentration during the oral glucose tolerance test) were performed in each cat on separate days, one without prior treatment (IGC) and the second with exenatide (1 μg/kg) injected subcutaneously 2 h before (ExIGC).
  9. 09AnimalAnimal study (in vivo)Pharmacokinetics

    In healthy cats, serum exenatide remained detectable in three of five cats eight hours after injection.

    In plain wordsIn cats, exenatide remained detectable in three of five animals eight hours after injection.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableLate serum detection
    Study

    catn = 5

    healthy neutered cats
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1 μg/kg · subcutaneousAs given in this study (cat).

    Source sentences

    Summary
    Exenatide was still detectable in the serum of three of five cats 8 h after injection.
    2 context sentences
    Summary · context
    Nine young, healthy, neutered, purpose-bred cats were used in a randomized, cross-over design.
    Summary · context
    Two isoglycemic glucose clamps (mimicking the BG concentration during the oral glucose tolerance test) were performed in each cat on separate days, one without prior treatment (IGC) and the second with exenatide (1 μg/kg) injected subcutaneously 2 h before (ExIGC).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.